June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
|Videos|March 24, 2021
What keeps ophthalmologists up at night: Part IV
Author(s)Alex Delaney-Gesing , David Hutton
Ophthalmologists share the most pressing issues on their mind within the glaucoma space — and why losing sleep from time to time may actually be a good thing.
Advertisement
Featured in this video:
Robert L. Stamper, MD; distinguished professor, Clinical Ophthalmology; director emeritus of the Glaucoma Service at University of California, San Francisco
Donald L. Budenz, MD, MPH; president, American Glaucoma Society; Kittner Family distinguished professor; chair, Department of Ophthalmology at the University of North Carolina, Chapel Hill
Ruth D. Williams, MD; of the Wheaton Eye Clinic (Wheaton, Illinois)
--
Watch the previous installments in the series:
Advertisement
Related to this article
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
2
Myopia control using spectacle lenses with highly aspherical lenslets
3
Demodex blepharitis: Diagnosis, treatment response, and recurrence
4
CHMP recommends ranibizumab biosimilar Fovlussea for retinal disease
5